MeCP2 is a fundamental protein associated with several neurological disorders, including Rett syndrome. It is considered a multifunctional factor with a prominent role in regulating chromatin structure; however, a full comprehension of the consequences of its deficiency is still lacking. Here, we characterize a novel mouse model of Mecp2 bearing the human mutation Y120D, which is localized in the methyl-binding domain. As most models of Mecp2, the Mecp2 Y120D mouse develops a severe Rett-like phenotype. This mutation alters the interaction of the protein with chromatin, but surprisingly, it also impairs its association with corepressors independently on the involved interacting domains. These features, which become overt mainly in the mature brain, cause a more accessible and transcriptionally active chromatin structure; conversely, in the Mecp2-null brain, we find a less accessible and transcriptionally inactive chromatin. By demonstrating that different MECP2 mutations can produce concordant neurological phenotypes but discordant molecular features, we highlight the importance of considering personalized approaches for the treatment of Rett syndrome.
Introduction
Mutations in the X-linked MECP2 (methyl-CpG-binding protein 2) gene cause a large spectrum of neurological disorders. Among these, Rett syndrome (RTT, OMIM #312750) was the first identified and remains the most thoroughly characterized MECP2-related disorder [1, 2] . RTT is a pediatric neurodevelopmental disease that typically affects girls, as males fail to survive beyond the first few years of life. Hallmark of typical RTT is the regression of language and hand use after a period of apparently normal development that usually lasts 6-18 months. During and after this regression phase, patients develop a host of symptoms that typically include intellectual disability, respiratory abnormalities, hand stereotypies, ataxia, absence of speech, autonomic dysfunctions, and epilepsy.
Although a comprehensive understanding of all its functions is still missing, MeCP2 is commonly defined as a ubiquitously expressed multifunctional protein mainly working as a transcriptional repressor. MeCP2, in fact, consists of two fundamental domains: a methyl-CpG binding domain (MBD) mediating its preferential binding to methylated DNA and a transcriptional repression domain (TRD) inhibiting gene expression through different mechanisms, including the recruitment of chromatin remodeling complexes to methylated DNA [3] [4] [5] [6] . Moreover, in mature neurons, where MeCP2 is very abundant, the protein acts as an alternative linker histone, organizing a specialized chromatin structure that dampens transcriptional noise [7] .
Even if most cases of RTT are caused by missense and nonsense mutations in MECP2, the first and so far most studied Mecp2 model has been the full knockout mouse, generated and described in refs. [8, 9] . However, to mimic RTT more closely, few more animal models carrying human pathogenic mutations have been generated [10, 11] .
Typically, Mecp2 mouse models recapitulate many RTT features. In particular, the hemizygous males appear grossly normal in the perinatal period, but later, they develop a progressive neurological phenotype whose onset and severity depend on the specific genetic mutation. These mice manifest locomotor deficits, hind limb clasping, hypotonia, reduced spontaneous movements, tremors, breathing defects, and seizures [10] . While the complete absence of Mecp2 results in a premature death, generally occurring between 56 and 80 days of life [8, 9] , the lifespan of knock-in mice can vary from 95 to 110 days to more than 300, according to the severity of the mutation [12] .
Interestingly, several lines of evidence suggest that in null animals, Mecp2 functions might be replaced by one or more other proteins, which therefore mask the consequences of its lack [7] . This suggests the importance of producing knock-in models that by ensuring the presence of the mutated protein, might provide better insights into MeCP2 functions [5, 10, [12] [13] [14] . For example, the Mecp2 R306C model was pivotal in revealing the recruitment of the NCoR/SMRT corepressor on DNA as a core MeCP2 function [5] . Similarly, Mecp2 T158M and Mecp2 R133C mutations in mice were instrumental to determine the role of the MBD on protein stability and chromatin binding [12] .
We have recently highlighted the relevance of Tyr-120 (Y120) residue for MeCP2 structure and function [15] . Its involvement in RTT was suggested by the identification of a patient carrying the pathogenic substitution of Y120 with aspartic acid (Y120D) [16] . The residue Y120 is located in the MBD of MeCP2, and it is highly conserved in mammals.
In accordance with its location, we proved that the substitution of residue Y120 with a D impairs the ability of the MBD to interact with DNA [15] . Accordingly, previous studies demonstrated that an exogenously expressed MeCP2-Y120D derivative features a decreased affinity for heterochromatin [17, 18] .
Based on these evidences and driven by the idea that specific mutations produce molecular consequences that might differ from the lack of Mecp2, we generated a novel mouse model carrying the human pathogenic mutation Y120D. We demonstrate that Mecp2 Y120D mice show a harsh behavioral phenotype that is only slightly less severe than Mecp2-null mice. At the molecular level, the Y120D mutation impairs the ability of Mecp2 to acquire a tight binding to chromatin mainly in mature neurons and to recruit corepressors on heterochromatin. As a consequence, compared to the Mecp2-null model, the Y120D adult brain is characterized by a globally more open chromatin structure. Our data suggest that, in spite of overlapping RTT-like symptoms, different mouse models of Mecp2 might display largely different molecular phenotypes, a novel perspective for the field of Mecp2 studies. Furthermore, while our results reinforce the idea that Mecp2 functions change with brain maturation [7, 19] , they challenge the general perception of the impact of Mecp2 mutations on neuronal chromatin architecture.
Materials and Methods

Plasmids
Human eGFP-MeCP2-WT and its mutant derivatives eGFPMeCP2-Y120D and -Y120F were obtained and described in [20] . The TBL1-mCherry construct [5] was kindly provided by Dr. Adrian Bird (Wellcome Trust Centre for Cell Biology, University of Edinburgh, UK).
Animal Husbandry
Both mouse lines were housed in the animal facility of the San Raffaele Scientific Institute of Milan. Generation of the knock-in (KI) mouse line is described in Supplementary Materials and Fig. S1 . Mecp2 Y120D/y males, heterozygous females, and wild-type (WT) controls were obtained by crossing heterozygous females with WT males of either C57BL/6J or CD1 background purchased from Charles River. Genotyping was performed through PCR on genomic DNA purified from tail biopsies, using the following primers: common forward 5′-CAGGGCCTCAGAGACAAGC-3′; common reverse 5′-GCAGATCGGCCAGACTTCC-3′; reverse for the KI allele 5′-GGGTTAATTGATATCCAATTGGGATCC-3′. A 300-bp fragment is common for WT and knock-in animals, while a 550-bp fragment is specific for the mutated one. When needed (e.g., embryos for primary cell cultures or small pups), the animal sex was determined by using primers recognizing Jarid1 (forward 5′-CCAGGATCTGACGACTTTCTACC-3′, reverse 5′-TTCTCCGCAATGGGTCTGATT-3′), which produce a PCR fragment only in males.
Mating and genotyping of the CD1 Mecp2 Bird mouse line are described in [21] .
All procedures were performed in accordance with the European Community Council Directive 2010/63/UE for care and use of experimental animals; all the protocols were approved by the Italian Minister for Scientific Research and by the San Raffaele Scientific Institutional Animal Care and Use Committee in accordance with the Italian law.
Phenotypic Evaluation
C57BL/6J or CD1 knock-in mice and WT littermates were weekly tested for the presence or absence of RTT-like symptoms with a previously described scoring system [22] . During each session, mice were weighed and scored for their general condition, mobility, hind limb clasping, and (only for CD1) tremor. Of note, the intermediate values of 0.5 and 1.5 were added to the canonical scores between 0 and 2 to provide a more detailed description of the phenotypic variability (for details see Supplementary Materials). All animals scoring 2 for general condition or tremor or rapidly losing weight were euthanized for ethical reasons. At the experimental endpoint, animals were euthanized through cervical dislocation after deep anesthesia with Avertin (Sigma-Aldrich, St Louis, MO, USA). At the time of death, brains were quickly removed and weighed, and cortices dissected on ice. Day of euthanasia was considered as day of death without distinguishing it from natural death.
Behavioral Assessment
Animals were maintained on an inverted 12-h light/darkness cycle at 22-24°C.
Rotarod Rotarod apparatus is composed by a horizontal rotating rod (diameter 3 cm) on which mice, separated by large disks, have to keep their balance. The test was carried out in 2 days. Each day, five trials of 5 min, separated by intervals of 30 min, were presented to the mice. On day 1, mice were placed on the apparatus with the rod rotating at 4 rpm (rotations/min) for 1 min, and then, the rotation speed was increased every 30 s by 4 rpm. On day 2, mice were tested at a constant rotation speed corresponding to the average of the maximum speeds reached from all mice during day 1. A trial ended when the mouse fell down or after 5 min. The latency to fall down from the rod was taken as the dependent variable for every trial and was normalized for the mouse weight.
Grip Grip test was performed with a horizontal metal bar (grip) strength dynamometer that mice grasp with the forelimb while suspended by their tail. Animals were gently pulled backward until they released the grip. The dependent variable was the maximal value obtained on a total of six trials.
Catwalk Gait analysis was performed by using CatWalk XT System (Noldus Information Technology, Wageningen, the Netherlands, http://www.noldus.com). Mice were allowed to freely ambulate along an illuminated glass plate within a confined corridor (50 × 8 cm) in a darkened room; footprints were recorded with a high-speed camera and subsequently analyzed with CatWalk XT 10.0 software (Noldus). Three trials/animal were analyzed and averaged to obtain stride length and base of support for front and hind right and left paws.
Spontaneous Alternation
The test was performed in a dim illuminated room and mice were habituated to the environment for 1 h before the test. The apparatus consisted in a cross maze with a central hub where the mouse was released and left free to explore for 10 min. Number and sequence of entries in each arm were recorded throughout the test. An alternation was considered correct when no more than one repetition over five entries was made.
Trace Fear Conditioning Auditory trace and delay fear conditioning were performed by placing the mice in an opaque conditioning chamber (L × W × H 25 × 17 × 23 cm; UgoBasile Instrument [Gemonio, Italy]) with a grid floor through which scrambled foot shocks could be delivered as unconditioned stimuli (US; 0.26-mA average intensity). The chamber was placed into a dimly lit (< 5 lx) sound attenuating box (background noise level 55 dB), and a speaker on top of the chamber allowed to deliver sounds as conditioning stimuli (CS; 2000 Hz).
All mice were pre-exposed to the test chamber for 10 min on the day before conditioning. Conditioning consisted in 1 min of baseline period (no stimulus) followed by five trials separated by 1 min of inter-trial intervals (ITI). In the trace fear conditioning, every trial is composed by the presentation of the CS (15 s) followed, 15 s later (trace), by the presentation of the shock for 2 s. The freezing behavior was measured during the presentation of the CS. Twenty-four hours after fear conditioning, mice were placed again in the conditioning box, measuring their freezing behavior in the context test and tone test. Context testing consisted of 2 min without CS (Bcontextual freezing^); tone testing consisted of 1 min without CS followed by 1 min with the CS turned on in a new environment. and plated on 0.1 mg/ml poly-L-lysine (Sigma-Aldrich) both on 6-multiwell plates at a density of 200,000 cells/well and on 24-multiwell plates (containing glass coverslips) at a density of 20,000 cells/well.
Data Analysis
Mecp2-null mouse embryonic fibroblasts (MEF) were prepared from Mecp2 −/y CD1 E14.5 embryos as previously described [20] . For DNA transfection, MEFs were plated on 12-multiwell plates on glass coverslips and transfected with lipofectamine 3000 (Invitrogen) as instructed by the manufacturer. Cells were analyzed 24 h after transfection.
Western Blot
Whole brains and cortices harvested from Mecp2 +/y and Mecp2 Y120D/y mice were mechanically homogenized with a Potter-ELV glass grinder in lysis buffer (50 mM Tris-HCl pH 7.4, 500 mM NaCl, 1% Triton X-100, 2 mM EDTA, 1 mM DTT, 1× PhosSTOP [Roche, Basel, Switzerland], 1× complete EDTA-free protease inhibitor cocktail [Roche]). Lysates were incubated 30 min on ice and sonicated (amplitude = 100%, three pulses for a total of 13 min). After centrifugation at 13,000 rpm at 4°C for 15 min, supernatant was collected. Neurons from 6-multiwell plates were directly lysed in Laemmli buffer 6× and sonicated (A = 100%, for 13 min). Proteins were electrophoretically separated on SDSpolyacrylamide gel and blotted on a nitrocellulose membrane using the Trans-Blot Turbo Transfer System from Bio-Rad (Hercules, CA, USA). Membranes were incubated 30 min in blocking solution (Tris-buffered saline containing 5% nonfat milk and 0.1% Tween-20, pH 7.4) and then incubated with the primary antibody diluted in blocking solution overnight at 4°C. The following primary antibodies were used: rabbit α-MeCP2 (1:1000; Sigma-Aldrich), mouse α-TuJ1 (1:10000; Sigma-Aldrich), rabbit α-rpS6 (5G10, 1:1000; Cell Signaling Technology, Danvers, MA, USA), rabbit α-P-rpS6 (Ser240/244, 1:1000; Cell Signaling Technology), rabbit α-P-S164 (1:1000; Covance, Princeton, NJ, USA), and rabbit α-H1 (1:1000; GeneTex, Irvine, CA, USA). Secondary antibodies were either fluorescent (1:2000 AlexaFluor 488; Life Technologies) or HRP-conjugated (1:10000; Cell Signaling Technology). Signals were visualized and acquired using the fluorescence laser scanner Typhoon FLA 9000 or using the chemiluminescence detection systems UVITEC ChemiDoc (Alliance 9.7, UVITEC Cambridge) or ChemiDoc Touch Imaging System (Bio-Rad). Quantitative analyses were performed using either ImageJ software or ImageLab software from Bio-Rad.
Immunofluorescence and Histology
Cells cultured on glass coverslips were washed with PBS and fixed in 4% paraformaldehyde (PFA) for 20 min at room temperature (RT). Neurons were then permeabilized in 0.1% Tween-20 for 10 min at RT and blocked for 1 h at RT (blocking solution 10% horse serum [Euroclone], 0.1% Triton X-100 in PBS), followed by an overnight incubation at 4°C with the rabbit α-MeCP2 primary antibody (1:100; Sigma-Aldrich) diluted in blocking solution. Cells were incubated with fluorescent secondary antibody (AlexaFluor 488 α-rabbit, 1:500 in blocking solution) for 1 h at RT. Finally, DNA was counterstained with DAPI (1:1000 in PBS; Invitrogen) for 10 min at RT, and coverslips were mounted with Prolong Gold reagent (Invitrogen).
Transfected MEFs were stained with DAPI (10 min at RT) after fixation. Images were acquired using Nikon microscope, objectives, and software.
Mice were transcardially perfused with 4% PFA. Brains were harvested, cryoprotected in sucrose 30%, and embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek, Alphen aan den Rijn, The Netherlands) and cut in 12-μm sections. Sections were washed thoroughly in PBS, antigen retrieved in 10 mM sodium citrate, washed in 0.01% Tween-20, and incubated in 0.1 M glycine. Tissues were blocked in blocking solution and incubated with antibodies as above (primary antibody: α-ATRX H-300 1:100, Santa Cruz Biotechnology, Dallas, TX, USA; secondary antibody: AlexaFluor 568 α-rabbit, 1:500). After counterstaining with DAPI, sections were mounted with Fluoromount-G (eBioscience, San Diego, CA, USA). Images were acquired using a Leica SP5 confocal microscope.
RNA Pol II-S5P staining was performed on nuclei isolated from Mecp2
, and Mecp2 −/y cortices at P40
(as described beneath in the chromatin accessibility assay section). In detail, nuclei were permeabilized in PBST (0.01% Triton X-100 in PBS), fixed in 4% PFA, and spotted on slides prior staining. Nuclei were then blocked for 1 h at room temperature (RT) and incubated overnight at 4°C with α-RNA Polymerase II-S5P (1:100, Abcam, ab5131). After washing in PBS, nuclei were incubated with AlexaFluor 488 α-rabbit (1:500; Life Technologies) for 2 h at RT, counterstained with DAPI for 10 min at RT, and finally mounted with Fluoromount-G (eBioscience). All images were acquired using a Leica SP5 confocal microscope, and the RNA Polymerase II-SP5 activity was evaluated by measuring the intensity of the nuclear α-RNA Polymerase II-S5P signal using ImageJ Software.
Salt Extraction Assay
Mecp2 chromatin affinity was assessed in brain tissues by performing salt extraction assays as described in refs. [3, 19] .
RNA Purification, cDNA Synthesis, and qPCR
Total RNA was extracted from Mecp2 +/y and Mecp2 Y120D/y cortices using the RNeasy Mini Kit (QIAGEN, Hilden, Germany) following the manufacturer's instructions. RNA quality was assessed on 1% agarose gel. Total RNA was retro-transcribed using the RT2 First Strand Kit (QIAGEN). qPCRs were performed using SYBR Select Master Mix (Applied Biosystems, Foster City, CA, USA) and the following primers:
Mecp2
-Forward: 5′ AAACCACCTAAGAAGCCCAAATC 3′ -Reverse: 5′ TTGACAACAAGTTTCCCAGGG 3′
18S
-Forward: 5′ GTAACCCGTTGAACCCCATT 3′ -Reverse: 5′ CCATCCAATCGGTAGTAGCG 3′
All samples were evaluated in triplicate and 18S was used as normalizer.
Calcium Imaging in Cultured Neurons
Cortical neurons at days in vitro (DIV) 4 or 13 were loaded wi th 5 mM of the rati ometric Ca 2 + dye Fura-2 pentacetoxymethylester (Sigma-Aldrich) dissolved directly in neuronal medium solution for 35-40 min at 37°C, washed, and transferred to the recording chamber of an inverted microscope (Axiovert 100; Zeiss, Oberkochen, Germany) equipped with a calcium imaging unit [23] . Fluorescence images were obtained by alternatively illuminating cells at 345 nm and 380 nm wavelength, and images (345 nm or 380 nm) were acquired at 1-Hz frequency. After baseline acquisition, neurons were stimulated with 100 μM NMDA (Tocris) followed by 50 mM KCl. Temporal Ca 2+ intensity profiles (expressed as ΔF340/380 fluorescence ratio) were calculated in discrete areas of interest from image sequences. Changes over baseline in the ΔF340/380 fluorescence ratio higher than B100^were considered Bcalcium peak.^To induce an appropriate NMDA stimulation, experiments were conducted in Mg 2+ -free Krebs-Ringer solution (KRH, in order to remove the Mg 2+ block from the receptor) with tetrodotoxin 1 mM (TTX), while the KCl-induced depolarization has been reached by using normal KRH with 1 μM TTX. Calcium transients were analyzed in about 150-200 cells per experimental group (as specified in legends). Nine glasses per group (one field/glass) were analyzed at each developmental point.
Chromatin Accessibility Assay
To maintain nuclei intact, Mecp2 Samples were incubated on ice for 10 min and centrifuged at 7000 rpm at 4°C for 10 min. Supernatants were discarded and nuclei were washed with buffer A. Nuclear pellets were resuspended in the digestion buffer B (50 mM NaCl, 10-mM pipes pH 6.8, 5 mM MgCl 2 , 1 mM CaCl 2 , 1× PhosSTOP, 1× complete EDTA-free protease inhibitor cocktail). Fifty microliters of each sample were collected, supplemented with 3 μl of 0.5 M EDTA and conserved as undigested fractions. The remaining volume was pre-warmed at 37°C and supplemented with 2.5 U of MNase (Worthington Biochemical Corporation, Lakewood, NJ, USA) per 10 million of nuclei. Digested fractions were collected at the indicated time points. MNase digestion was stopped by adding 3 μl of 0.5 M EDTA to each fraction. DNA was phenol/chloroform extracted and quantified. For each fraction, 10 μg of DNA was loaded on a 2% EtBr agarose gel, which was run for approximately 5 h. For each time point, ImageJ was used to obtain a densitometry plot and the amount of mononuclesomal DNA normalized on total DNA was plotted to highlight differences in the digestion rate between experimental groups.
DAPI Staining of MNase-Treated Nuclei
Fresh isolated nuclei were obtained as above. Samples were resuspended in 300 μl of buffer B and 2.5 U/50 μl of MNase were added. Reactions were performed at 37°C and stopped at 0, 5, and 10 min by adding 3 μl of 0.5 M EDTA. Nuclei were then fixed in 4% PFA for 5 min, spotted on a glass coverslip and stained with DAPI for 10 min at RT. Nuclei were mounted with Fluoromount-G and imaged using a Leica SP5 confocal microscope. DAPI intensity and heterochromatin area were calculated by using ImageJ software.
5-hmC DNA ELISA Assay
Brain cortices were harvested from Mecp2 
Results
Mecp2 Y120D Knock-in Mice Manifest a Severe RTT-Like Phenotype and Short Lifespan
The mouse line carrying the human Y120D mutation was generated on a C57BL/6J background (Mecp2 Y120D mice; Fig. 1a ; see Supplementary Materials and Fig. S1 for a detailed description of the procedures). Sequencing of hemizygous mutant mice, screened by PCR, proved the presence of the expected mutation (Fig. 1b) .
While the colony was maintained on a C57BL/6J background, the mutant allele was also transferred on a CD1 (ICR) genetic background; the advantages of the CD1 background in Mecp2 studies are described in ref. [21] . Colonies were maintained by crossing heterozygous females to wildtype (WT) males, since hemizygous males were unable to induce pregnancy. To be noticed, the generated mutation does not affect Mecp2 mRNA levels (Fig. 1c) .
The severity of the Mecp2-Y120D mutation was evaluated using a well-established panel of parameters which include lifespan and phenotypic score [22] . As depicted in Fig. 1d , hemizygous Mecp2 Y120D males died prematurely (average lifespan of 97 and 121 days in the C57BL/6J and CD1 background, respectively). After weaning, mutated males became progressively symptomatic, as indicated by the increased phenotypic score ( Fig. 1e; Supplementary Materials and Fig. S2 ). On the other hand, heterozygous CD1 Mecp2 Y120D females started showing typical RTT-like features only at 9 weeks of age ( Fig. 1f; Supplementary Materials and Fig. S2 ), and they did not manifest any apparent reduced longevity in the first year of life. C57BL/6J heterozygous females were not analyzed in this study because in a time frame of over 2 years, we did not succeed in generating a sufficient number of animals. In both sexes, similarly to null animals [21] , tremor was the first symptom to appear along with worsening of the general conditions, while hind limb clasping and altered mobility appeared later and were characterized by higher variability (Supplementary Materials and Fig. S2 ). Body weight of Mecp2 animal models generally depends on mutation, sex, and genetic background [21] ; indeed, C57BL/6J Mecp2-null mice are notoriously underweight compared to WT, while the corresponding females are generally heavier. Compared to WT, Mecp2-null male animals on a CD1 background show no difference in body weight both at early and late postnatal time points. However, CD1 heterozygous females have a strong tendency towards obesity [21] . Our data show that while C57BL/6J Mecp2 Y120D males were always lighter than WT littermates, CD1 mutated males showed a tendency to be lighter soon after birth, while becoming generally overweight in adulthood (Fig. 1g) . Conversely, the body weight of CD1 Mecp2 Y120D heterozygous females was indistinguishable from WT littermates at early postnatal days, but it progressively increased with aging, leading to obesity (Fig. 1h ).
An early diagnostic criterion for Rett syndrome is deceleration of head growth, which often leads to microcephaly in infancy. Similarly, most of the Mecp2 animals generated so far (with the exception of the Mecp2 308X mice [24] ) are characterized by decreased brain size and weight. We weighed brains of pre-(P18) and symptomatic (P40 and P>130) CD1 Mecp2 Y120D males. Compared to WT, CD1 mutant brains exhibited an overall weight reduction of 12%, 13.5%, and 17.5% at P18, P40, and P>130, respectively; brains from symptomatic C57BL/6J Mecp2 Y120D males (P > 80) had a 15.7% of weight reduction compared to WT brains (Fig. 1i) .
The presence of RTT-like phenotypes was also analyzed through a battery of behavioral tests on CD1 Mecp2 Y120D male mice and littermate controls. Results are summarized in Fig. 2 and Table S1 . Rotarod (Fig. 2a) , CatWalk (Fig. 2b, c) , and grip (Fig. 2d) tests highlighted significant deficits in motor coordination, gait, and anterior paws strength in juvenile (P30) and/ or adult (P60) Mecp2 Y120D mice. We next examined learning ability of P30 and P60 Mecp2 Y120D mice by performing the spontaneous alternation test. Working memory impairment was evident at P30, when knock-in mice showed more than 30% reduction of correct responses with respect to controls, with no difference in the total number of visits (Fig. 2e) . P60 data have been omitted since the considerable decrease in spontaneous locomotor activity confounded the interpretation of results. We also found a deficit in associative memory through contextual and cued fear-conditioning tests (Fig. 2f) . Juvenile and adult knock-in mice showed significant reduced freezing during the cue exposure 24 h after training, suggesting a specific impairment in , as mean ± s.e.m. Significance is calculated by Student's t test. d Mecp2 Y120D/y mice in C57BL/6J and CD1 background (n = 8 and 11, respectively) show reduced lifespan compared to Mecp2 +/y littermates (n = 6 and 9, respectively). Significance is calculated by Log-rank (Mantel-Cox) test (*P < 0.05, ****P < 0.0001). e Plots showing the progression of the phenotypic score (cumulated for general condition, mobility, hind limb clasping, and-only for CD1-tremor values) of C57BL/6J and CD1-mutated males (animals evaluated: n = 6 C57BL/6J and 10 CD1 Mecp2 Y120D/y vs 7 C57BL/6J and 9 CD1 Mecp2 ). Analyses ended when there were less than three animals per group. Data are represented as mean ± s.e.m. Significance is calculated by multiple t test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). ). Analyses ended when there were less than three animals per group. Data are represented as mean ± s.e.m. Significance is calculated by multiple t test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). i Brain weight was measured in juvenile (P18, n = 4 Mecp2 Y120D/y vs 7 Mecp2 +/y ), young adult (P40, n = 18 Mecp2 Y120D/y vs 14 Mecp2 +/y ), and adult (CD1 P > 130 n = 4 per genotype, C57BL/6J P > 80 n = 5 per genotype) mice. Measures of brain weights are expressed as mean ± s.e.m. Significance is calculated by Student's t test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001) the conditioned stimulus memory. By performing most of these tests also with CD1 Mecp2-null mice, we revealed that both Mecp2 lines manifest very similar behavioral performances (Fig. S3) .
Anxiety-like and explorative behaviors were also assayed through different approaches (Supplementary Materials and  Table S1 ), but no significant defect was observed. Notably, while anxiety is a common trait of RTT patients, in Mecp2 animal models, this feature depends on the specific genetic mutation [25] .
We completed the preliminary assessment of phenotypes typically evaluated in Mecp2 animal models by testing whether knock-in neurons exhibit functional defects similar to the Mecp2-null cells. We recently demonstrated that both in vivo and in vitro Mecp2-null neurons are characterized by a delayed maturation and impaired intrinsic responsiveness to external stimuli [26] . Thus, we cultured E15.5 Mecp2 Y120D cortical neurons and probed neuronal responsiveness; the analyses were performed on immature (DIV4) or more mature (DIV13) neurons (Fig. 2g) . Calcium imaging analyses showed that the amplitude of KCl-induced calcium transients is reduced in mutated neurons both at DIV4 and 13, confirming an impairment in the expression/sensitivity of voltageoperated calcium channels (VOCCs) and consequently a defective neuronal responsiveness to depolarization. Calcium imaging was also used to obtain information on the expression of functional NMDA receptors (Fig. 2h) . Whereas immature Mecp2 Y120D neurons showed a significant reduction in NMDA-induced calcium peaks, mature neurons exhibited normal calcium transients associated with NMDA stimulation in spite of lower response to KCl. These data confirm that Mecp2 mutations affect neuronal responsiveness; further, they suggest that Mecp2-related phenotypes change along neuronal maturation.
Y120D Mutation Affects Mecp2 Abundance and Chromatin Binding Mainly in Mature Neurons
To gain insights into the molecular mechanisms responsible for the phenotypes affecting Mecp2 Y120D mice, we assessed Mecp2 levels and other molecular markers typically associated with Mecp2 functions. The results show that, while Mecp2-Y120D levels were normal in immature brains (E16, P6), they were significantly lower at P18 (− 56 ± 4%, ***P < 0.001, Student's t test; Fig. 3a ) and P40 (− 62 ± 4%, ****P < 0.0001, Student's t test ; Fig. 3a) ; a similar pattern was confirmed in in vitro cultured neurons (DIV7 − 29.7 ± 12.3%; DIV14 − 35.7 ± 13.3%, *P < 0.05, Student's t test; Fig. 3b ).
In line with the Mecp2-null model, the mature knock-in brain (P40) exhibited a reduction in rpS6 phosphorylation (− 43 ± 4%, *P < 0.05, Student's t test; Fig. 3c, upper panel) , a hallmark of RTT progression [27, 28] . Recently, we have demonstrated that phosphorylation of MeCP2 on Ser164 (S164), which is downregulated during neuronal maturation, globally diminishes MeCP2 binding to chromatin [19] . We thus assessed the levels of this phosphorylation in Mecp2 Y120D/y adult mice, finding that it is significantly increased compared to WT (+ 193 ± 30%, ***P < 0.001, Student's t test; Fig. 3c, lower panel) .
Since a 50% reduction of protein levels in mice cannot explain the severity of the observed phenotype [29] , we proceeded analyzing the consequences of Y120D mutation on Mecp2 activity. Previous studies demonstrated that the MeCP2-Y120D mutant exogenously expressed in nonneuronal cells shows a reduced accumulation on heterochromatic foci [17, 18] . To confirm these results in cells expressing Y120D/y mice show decreased percentage of correct alternation with the same number of entries compared to WT animals. f Impaired tone (cue; conditioned stimulus CS) memory in P30 Mecp2 Y120D/y (n = 13) and P60 Mecp2 Y120D/y (n = 22) mice compared to their Mecp2 +/y littermates (P30, n = 15; P60, n = 9) during the auditory fear conditioning test. Graphs represent the percentage of freezing during the five tones (CS) of training phase (left panels), during the context test 24 h after training (middle panels) and during the cue test (right panels). Data are presented as means ± s.e.m. For statistical analyses, see BMaterials and Methods^(*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). g Calcium imaging experiments in cultured E15.5 cortical neurons reveal precocious and persistent functional alterations in Mecp2 Y120D/y neurons. Representative traces and relative quantification of KCl-induced calcium transients in WT and Mecp2 physiological levels of Mecp2, we compared the sub-nuclear localization of the WT and mutated proteins in cultured cortical neurons (Fig. 3d) . As expected, while the WT protein showed a clear accumulation on highly methylated heterochromatic foci starting from DIV7, Mecp2-Y120D remained mainly diffused in the nucleus along all stages of neuronal maturation, forming only few dots that do not overlap with DAPI-positive foci. Our data thus suggest that the pathogenic mutation might directly and/or indirectly (through S164 phosphorylation [19] ) impair Mecp2 affinity to chromatin, with the magnitude of the effect depending on brain maturation. Thus, through salt extraction experiments, we compared the affinity for chromatin of the WT and mutated protein in immature (P6) and mature (P40) mouse brains (Fig. 3e-g ). As reported [19] , in mature brain, WT Mecp2 is more tightly associated with chromatin compared to the immature brain. On the contrary, at P40, most of the mutant protein was extracted at 300 mM NaCl, therefore failing to acquire a tighter association with chromatin (Fig. 3f) . To confirm this result with a complementary assay, an equal amount of brain nuclei isolated from WT and Mecp2 Y120D animals (P40) were incubated in buffers with increasing ionic strength and the amount of extracted Mecp2 analyzed by western blot (Fig. 3g) . As already demonstrated [3] , WT Mecp2 was increasingly extracted at higher salt concentrations; indeed, the highest signal was observed at 1 M NaCl, while almost no Mecp2 was detectable at 200 mM NaCl. On the contrary, most of Mecp2-Y120D was extracted with a much lower concentration of NaCl (300-400 mM) with no further increase at 1 M NaCl. Notably, the overall amount of the mutant protein was generally decreased in accordance with the protein levels depicted in Fig. 3a . Although the affinity for chromatin of WT and mutated Mecp2 diverged more clearly in mature brain, quantification of three independent experiments revealed that at P6, Mecp2-Y120D is already less tightly bound to chromatin (Fig. 3e) .
Together, these data suggest that the Y120D mutation impairs both Mecp2 binding to chromatin and protein levels and that these phenotypes become progressively more evident when the WT MeCP2 acquires mature structural functions [7, 19] .
Mecp2
Y120D and Mecp2-Null Brains Exhibit Different Chromatin Compaction
Mecp2 is known to interact with different chromatin remodeling complexes, and it is considered to play a major role in neuronal chromatin architecture [4, 30] . We thus addressed whether Mecp2-Y120D maintains its ability to interact with relevant corepressors, such as NCoR and ATRX and whether this mutation affects chromatin compaction.
Mecp2-null MEFs were cotransfected with eGFP or eGFPMeCP2 derivatives and TBL1-mCherry, and the ability of MeCP2 isoforms to recruit TBL1, part of the NCoR complex, on heterochromatin foci was assessed. In accordance with [5, 31] , we demonstrated that no cell transfected with eGFP showed co-localization of TBL1-mCherry with heterochromatic foci (Fig. 4a) , whereas TBL1 was efficiently recruited on the DAPI-positive heterochromatic foci in 58% of cells expressing eGFP-MeCP2-WT and in 45% of cells expressing eGFP-MeCP2-Y120F. Importantly, only in 19% of cells expressing MeCP2-Y120D, TBL1-mCherry colocalized with the heterochromatic foci, suggesting that the interaction between Mecp2 and NCoR is significantly affected by the Y120D mutation. Of relevance, the presence of smaller and less bright green foci in cells that exogenously express eGFPMeCP2-Y120D compared to cells transfected with eGFPMeCP2-WT and eGFP-MeCP2-Y120F confirmed the impaired chromatin binding ability of the Y120D mutant.
Considering that the localization of the chromatin remodeling protein ATRX on pericentric heterochromatin of mouse neurons depends on its interaction with the MBD of Mecp2 [3, 6] , we proceeded investigating and revealing a drastic change in ATRX localization in the Mecp2 Y120D brain with respect to controls (Fig. 4b) . Together, these data confirm that the missense mutation Y120D alters the ability of MeCP2 to interact with and/or properly recruit on chromatin its corepressors, therefore affecting their sub-nuclear distribution. Given that such corepressors concur to chromatin landscaping, a , as mean ± s.e.m. Significance is calculated by Student's t test (***P < 0.001, ****P < 0.0001). b Representative images and western blot quantification of Mecp2 protein levels of Mecp2 Y120D/y and Mecp2 +/y E15.5 cortical neurons at different DIVs (n ≥ 10 per genotype at each time point). Data are represented relative to Mecp2 +/y , as mean ± s.e.m. Significance is calculated by Student's t test (*P < 0.5). c Western blot quantification showing altered P-rpS6 and P-S164 levels in cortices of P40 Mecp2 Y120D/y CD1 mice (n = 7 Mecp2 Y120D/y vs 5 Mecp2 +/y ). Data are represented relative to Mecp2 +/y , as mean ± s.e.m. Significance is calculated by Student's t test (*P < 0.5, ***P < 0.001). d Representative images of Mecp2 +/y and Mecp2 Y120D/y cultured neurons established from E17.5 cortices and immunostained at different DIV for DAPI (left panels) and Mecp2 (middle panels). Mecp2 Y120D/y nuclei show diffused staining that does not overlap with DAPI-heterochromatic foci (white arrows). Images were taken at × 100 magnification. e, f Upper panels: representative western blots showing salt extraction of WT or mutant Mecp2 with increasing concentrations of NaCl from P6 and P40 mouse CD1 brains. H1 was included as control of the salt extraction procedure. Lower panels: quantification of the fraction of WT and Y120D Mecp2 extracted with different concentration of NaCl. Data are represented as mean ± s.e.m. Significance is calculated by twoway ANOVA followed by Bonferroni post hoc test (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). g Nuclei were purified from Mecp2 +/y and Mecp2 Y120D/y P40 brains and resuspended in buffers containing 200 mM, 300 mM, 400 mM, or 1 M NaCl. Extracted Mecp2 was tested by western blot (n = 2) time course of micrococcal nuclease (MNase) digestion of P6 and P40 brain nuclei was performed to analyze chromatin accessibility (Figs. 5a and S4) . Interestingly, while we were unable to detect any overt phenotype in the immature brain (Fig. S4) , the MNase digestion pattern at P40 of the Mecp2 Y120D/y sample showed a slightly faster accumulation of fragments corresponding to mononucleosomal DNA normalized on total DNA (Fig. 5a) . Quantification of three different experiments demonstrated a consistent trend that, however, did not reach the statistical significance (Fig. 5b') . By digesting WT and Mecp2-null chromatin, the mutant sample appeared mildly less accessible; this tendency was confirmed by quantifying three independent experiments (Fig. 5b^) . Since these results might suggest that the complete absence of Mecp2 leads to compensatory mechanisms that differ from those generated by the presence of the mutated Mecp2, we corroborated these data with a complementary approach. Neuronal nuclei were thus purified from Mecp2 Y120D/y or Mecp2-null adult (P40) cortices and the corresponding WT control tissues, and heterochromatic and euchromatic accessibility was assessed by staining purified nuclei with DAPI at different time points of MNase digestion. By measuring both the stained area in heterochromatic foci (Fig. 5c', left panel) and the average DAPI intensity (Fig. 5c^, left panel) in Y120D samples, we revealed that euchromatic and heterochromatic DNA is more rapidly digested in mutant nuclei, therefore suggesting a globally more accessible chromatin structure. Conversely, MNase treatment of Mecp2-null nuclei demonstrated that their heterochromatic DNA, but not bulk chromatin, is less digested than the control (Fig. 5c' , c^, right panels). To verify whether this change in chromatin accessibility results in any functional alteration, transcriptional activity within single cortical nuclei was investigated by measuring the levels of phosphorylated RNA polymerase II (Pol II-S5P) in Mecp2 Y120D/y or null P40 nuclei and their corresponding WT controls (Fig. 5d [32-35] ). Signal specificity was confirmed by the lack of co-localization between DAPI foci (transcriptionally silent heterochromatin) and Pol II-S5P signal (transcriptionally active chromatin, Fig. 5d ). Importantly, a strong and significant increase of Pol II-S5P in Mecp2 Y120D/y nuclei was observed (+ 53.4 ± 1.3%, ****P < 0.0001, Student's t test; Fig. 5d') , while the null nuclei showed a slight but significant reduction with respect to their controls (− 22.9 ± 0.9%, ****P < 0.0001, Student's t test; Fig. 5d^) .
Eventually, we reinforced these data analyzing whether WT, Mecp2-null, and Mecp2 Y120D/y mature brain cortices (P40) differ in their 5-hydromethylcytosine (5-hmC) content. In fact, a direct relationship between genome accessibility, transcriptional activity, and 5-hmC levels has recently been proposed [36, 37] . In particular, methylated CG dinucleotides contained in highly compact chromatin are less frequently converted to 5-hmC, probably because of lower accessibility of Tet hydroxylases [36] . Figure 5e demonstrates that while Mecp2 Y120D/y cortices manifest a tendency to an increase in 5-hmC levels, Mecp2-null adult brains display a small but significant decrement, as already reported for Mecp2-deficient granule cells [38] .
Overall, these data support our hypothesis that the presence of Mecp2-Y120D diversely affects the general features of brain chromatin compared to the total absence of Mecp2. 
Discussion
The generation of several mouse models carrying different Mecp2 alterations proved instrumental to investigate MeCP2 functions and its involvement in Rett syndrome and MECP2-related disorders [10, 13] . Mecp2-null animals [8, 9] were the first model generated and still represent the mostly used one. However, it has recently become evident that when Mecp2 is absent, its functions are replaced by compensatory mechanisms that might mask and confound the consequences of its loss [7] . These results highlighted the importance of producing other models with less severe genetic lesions, possibly mimicking human mutations [5, 10, [12] [13] [14] . Our manuscript describes the generation and the behavioral and molecular characterization of a novel knock-in mouse model of Rett syndrome carrying the human missense mutation MECP2-Y120D, resulting in the substitution of tyrosine 120 (Y) with an aspartic acid (D) [16] . Although the Y120 residue of MeCP2 has been linked to RTT only once so far, its involvement in MeCP2 affinity for heterochromatin has already been proved [17, 18] . Through molecular dynamic simulations, we have recently demonstrated that the Y120D mutation leads the methyl binding domain (MBD) of MeCP2 to sample an alternative conformational space that impairs its ability to interact with DNA. These results have been experimentally confirmed in electrophoretic mobility shift assays comparing the ability of WT and Y120D MBD polypeptides to bind methylated and unmethylated DNA [15] . Interestingly, the conversion of Y120 into F did not affect the DNA binding properties of the MBD of MeCP2. Similarly, here, we demonstrate that WT and Y120F MeCP2 show a similar ability to recruit TBL1 on heterochromatin, while the mutant Y120D protein has lost such ability. All in all, these data suggest that harboring a tyrosine residue is not crucial for MeCP2 functions, while its conversion into aspartate, or possibly in a negatively charged residue, is a key detrimental step.
In line with the clinical features of the Y120D RTT patient [16] , the Y120D mutation in mice leads to a harsh condition that is only slightly less severe compared to the total absence of the protein. Indeed, a progressive deterioration of the animal condition, in particular of the neurological aspects (mainly related to mobility, learning, and memory functions), becomes overt after a short period of apparently normal development, and eventually, these mice die prematurely.
The molecular characterization of this novel mouse model revealed several features that are highly relevant for research on MeCP2 and Rett syndrome.
First, although the Y120D mutation is supposed to impair Mecp2 binding to DNA, the molecular phenotypes associated with the mutant protein (reduced affinity for chromatin, inability to accumulate on heterochromatic foci, and bulk increase in chromatin accessibility) become evident mainly in mature neurons when protein levels are also halved. We recently suggested that Mecp2 changes its functions during brain maturation [19] . In particular, in developing brains and neurons, the protein is not tightly bound to chromatin and largely cosediments with nucleosome-free DNA. Possibly due to diverse post-translational modifications (i.e., phosphorylation) during brain maturation, MeCP2 attains a tight association with nucleosomal DNA and chromatin, probably also acquiring structural functions, as already proposed [7] . Thus, it is conceivable that the molecular consequences of harboring the missense mutation Y120D become more severe in adult brain, when mutant MeCP2 fails in acquiring its expected structural functions. Nevertheless, the impaired DNA binding is expected to somehow affect the transcriptional properties of MeCP2 also in early development, therefore leading to functional alterations. Accordingly, we demonstrate that early responsiveness to stimuli of Mecp2 Y120D cultured neurons is impaired. Theoretically, all MeCP2 mutants characterized by a reduced DNA binding should share the herein described molecular phenotypes. Indeed, an effect on protein stability of the RTT mutations T158M and R133C has already been proved. Interestingly, destabilization of mutant Mecp2 appeared to positively correlate with the reduction in DNA binding [12, 14] . However, in apparent discordance with our results, the Mecp2 T158A mouse shows a significant decrement in protein levels already at perinatal age that worsens with time [14] . Similarly, Lamonica et al. found that the protein expression levels of the mutant Mecp2 T158M are reduced of almost 20% at P0 and further decreased at P7 and P15; no further decrement was observed beyond this developmental stage [39] .
So far, it is not clear why mutations in T158 cause an earlier effect on protein levels compared to Y120D. We propose that unbound Mecp2 is more rapidly degraded in mature neurons than in immature cells, which are physiologically characterized by a more dynamic association of the protein with chromatin. In addition, as already suggested [40] , Mecp2 degradation might be affected by its post-translational modifications and it is conceivable that Mecp2-Y120D is diversely modified with respect to T158A/M. Accordingly, we demonstrate that the Mecp2 Y120D/y mature brain exhibits a significant increase in S164 phosphorylation. However, since the Y120D mutation somehow mimics the effect of Y120 phosphorylation that occurs more frequently in the immature brain [15] , it is also possible that the Y120D missense mutation has a minor impact on the developing brain compared to the T158M/A mutations. Thus, although in the future, we will investigate whether a different combination of post-translational modifications occurs on Mecp2-Y120D, currently, we cannot exclude that the mutated Mecp2 T158M protein is more impaired in its DNA binding properties and therefore more effectively degraded in the brain since early development.
Several studies suggest that one of the most relevant activities of MeCP2 in brain is the recruitment of corepressors on methylated DNA, leading to an inaccessible and transcriptionally silent chromatin structure [4, 30] . Considering that in mature neurons, the protein is so abundant to bind the majority of methylated cytosines, its effects are likely exerted on the whole genome (Fig. 6, BWT^) . We demonstrate that in cells expressing the Y120D mutant, the molecular partners of Mecp2, such as NCoR and ATRX, are not properly recruited on heterochromatin. As a result, in the Mecp2 Y120D mature brain, chromatin is globally more accessible compared to WT brain, in line with the increased levels of S5 phosphorylated RNA Polymerase II and the concomitant increase in 5-hmC levels, suggesting an increased transcriptional activity (Fig. 6, BY120D^) . Unexpectedly, the consequences of the total absence of Mecp2 are quite different and do not appear to cause the hypothesized general decrease in chromatin compaction [19] . Indeed, we found that mature Mecp2-null brains do not have a more accessible chromatin structure, but instead exhibit a reduced MNase accessibility particularly on heterochromatic DNA. Furthermore, Mecp2-null brain nuclei manifest reduced levels of actively transcribing RNA polymerase II and 5-hmC. Skene et al. proposed that in mature neurons, MeCP2 acts as a chromatin architectural factor whose absence is compensated by the up-regulation of histone H1 [7] (Fig. 6 , Bnull^). Our data not only confirm the existence of compensatory mechanism(s) but also suggest that these compensations lead to a more packed chromatin structure. In possible accordance, several studies profiling transcription in Mecp2-null brains unexpectedly reported the down-regulation of the majority of differentially expressed genes [4, 27] ; further, it has been suggested that histone H1 stabilizes a tighter chromatin structure compared to MeCP2 [41] .
These data highlight that although mutations of Mecp2 might produce largely concordant behavioral phenotypes in mice, they can diversely compromise Mecp2 functions, therefore leading to discordant compensatory mechanisms and/or alterations in chromatin structure. Although future studies will reveal the extent to which these diversities affect transcriptional profiles, our results indicate that effective therapeutic strategies might differ depending on the specific genetic mutation. For example, by increasing the expression of Mecp2-T158M, Lamonica et al. demonstrated that the reduced levels of the mutant protein are contributing to RTT pathogenesis [39] . Considering that mutations in the MBD might generally destabilize MeCP2, the authors proposed that therapies able to stabilize or increase the expression of mutant MeCP2 might have the potential to benefit most RTT patients carrying −/y littermate cortices. Purified nuclei were digested with MNase for 5 and 10 min before staining. Undigested nuclei (UT) were DAPI stained for comparison (n = 60 to 110 nuclei for each experimental group). Heterochromatic area stained by DAPI was measured in Mecp2 Y120D/y nuclei and Mecp2-null nuclei (c'), while total nuclear intensity is displayed in c^. Data are expressed as percentage of the untreated WT and are represented as mean ± s.e.m. Significance was calculated by two-way ANOVA followed by Bonferroni post hoc test (**P < 0.01, ***P < 0.001, ****P < 0.0001). Y120D/y brains. Several studies have proposed that in brain MeCP2 is globally bound to chromatin where it recruits different remodeling chromatin complexes, therefore leading to a specialized chromatin structure (BWT^panel). Loss of MeCP2 protein would lead to compensatory mechanisms that double histone H1 levels [7] and lead to a more condensed and transcriptionally inert chromatin structure (Bnullp anel). In the Y120D knock-in brain, the labile interaction between MeCP2 and DNA, and the concomitant delocalization of its corepressors such as NCoR and ATRX lead to a more accessible and transcriptionally active chromatin structure (BY120D^panel) mutation in the MBD of MeCP2. However, we propose that the stabilization therapy might not be so beneficial in patients carrying a mutation that impairs the fundamental interaction of MeCP2 with NCoR [42] , as it occurs with the MeCP2-Y120D alteration. The molecular mechanism by which Y120D mutation impairs the NCoR binding is possibly due to a general change in the motions/dynamical profile of the MBD, while the T158M mutation mainly affects the structure of the domain [14] . Indeed, we demonstrated that, despite Y120 is not in direct contact with DNA, its mutation in D leads to an altered mobility of the domain and to a defective communication between the domain residues [15] . This impaired communication and profile of mobility/ flexibility can be propagated to the entire protein, thus affecting the interaction with NCoR/SMRT. This longrange communication between the two protein domains could explain why the T158M and Y120D mutations have a different effect on the protein function although they are both located in the MBD.
To conclude, we suggest that only a thorough comprehension of the molecular alterations that affect Mecp2-null and knock-in animal lines mimicking human pathogenic mutations will truly highlight the molecular consequences of MeCP2 deficiency and the possible existence of convergent molecular defects. Emphasis should be given on comparing Mecp2-null models with animals carrying human mutations that affect or not affect MeCP2 binding to DNA together (or not) with an influence on its ability to associate with its interactors. These comparisons will help clarify whether treatment of MECP2-related diseases should consider a personalized approach in which patients are stratified in subgroups based on the molecular consequences of their genetic lesion.
